Abstract：
An important preventive measure to mitigate the COVID-19 pandemic is vaccine implementation. In creating vaccines, evoking neutralizing antibody (NAb) production is the main objective. This review determines and compares the NAb titers produced by COVID-19 vaccine recipients based on the vaccine type and the manner of administration. This review includes published articles on studies with healthy participants with a minimum age of 18 years, without previous infections, and those who were given Emergency Use License (EUL) vaccines from WHO. Bias assessment was performed using the Cochrane Risk of Bias and the Newcastle- Ottawa Scale. In all the studies, 40.82% of the primary doses were viral vector platforms. For booster doses, 50% were mRNA platforms. Messenger RNA (mRNA) vaccines have higher titers as homologous than as heterologous vaccines. However, inactivated vaccines and viral vector vaccines have lower titers as homologous than as heterologous vaccines. Meanwhile, subunit vaccines lack data for their titers. Based on the antibody titers, homologous mRNA vaccines are more viral-protective than their heterologous counterparts. Heterologous inactivated and viral vector vaccines are more protective than homologous combinations, mainly when mRNA is the other type in those heterologous combinations. This is because mRNA vaccines elicit higher immunogenicity compared to other types.
摘要：
缓解COVID-19大流行的一项重要预防措施是实施疫苗。在制造疫苗时，引起中和抗体（NAb）的生产是主要目标。这篇综述根据疫苗类型和给药方式确定和比较了COVID-19疫苗接受者产生的NAb滴度。这篇综述包括发表的关于最小年龄为18岁的健康参与者研究的文章，没有以前的感染，以及获得世卫组织紧急使用许可证(EUL)疫苗的人。使用Cochrane偏差风险和Newcast-Ottawa量表进行偏差评估。在所有的研究中,40.82%的主要剂量是病毒载体平台。对于加强剂量，50%为mRNA平台。信使RNA(mRNA)疫苗在同源时比在异源疫苗时具有更高的滴度。然而,灭活疫苗和病毒载体疫苗在同源时的滴度低于异源疫苗。同时,亚单位疫苗缺乏滴度数据。根据抗体滴度,同源mRNA疫苗比异源疫苗更具病毒保护性。异源灭活疫苗和病毒载体疫苗比同源组合更具保护性,主要是当mRNA是那些异源组合中的另一种类型时。这是因为与其他类型相比,mRNA疫苗引发更高的免疫原性。
